Moleculin Biotech, INC DEF 14A proxy statements

Moleculin Biotech, Inc. calls a Special Meeting to approve the issuance of up to 2.61 million shares from warrant exercises and a corporate name change to Moleculin Inc.

Moleculin Biotech, Inc. calls a Special Meeting to approve the issuance of up to 64.86 million shares from warrant exercises and a corporate name change to Moleculin Inc.

Moleculin Biotech, Inc. has filed definitive additional proxy materials with the U.S. Securities and Exchange Commission.

Moleculin Biotech, Inc. is seeking shareholder approval for a significant increase in authorized common stock, a potential reverse stock split, and the issuance of shares related to recent warrant exercises, alongside executive compensation and board elections at its upcoming Annual Meeting.

Moleculin Biotech is seeking stockholder approval to issue shares upon the exercise of warrants issued in a private placement to comply with Nasdaq Listing Rule 5635(d).

Moleculin Biotech, Inc. has filed a definitive proxy statement with the SEC.

Moleculin Biotech is holding its annual stockholder meeting on October 24, 2024, to vote on key proposals including the election of directors, ratification of the accounting firm, approval of a new equity incentive plan, and amendments to existing warrants.